MicroVue™ SC5b-9 Plus EIA
The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens.
Product Specifications
Citations | 97 |
---|---|
Specimen |
Serum 10 μL, EDTA or Citrated Plasma 50 μL |
LLOQ | 8.8 ng/mL |
ULOQ | N/A |
Assay Time | 2 hours |
Cross Reactivity |
African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey |
Ordering Information
Catalog Number | A020 |
---|---|
Catalog Number (CE) | A029 |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 650,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Serum 10 μL, EDTA or Citrated Plasma 50 μL |
Limit of Detection (LOD) | 3.7 ng/mL |
Lower Limit of Quantitation (LLOQ) | 8.8 ng/mL |
Upper Limit of Quantitation (ULOQ) | N/A |
Intra Assay | 1.6–6.8% |
Inter Assay | 5.0–13.1% |
Standards | 5 |
Controls | 2 |
Sample Values |
None |
Assay Time | 2 hours |
Cross Reactivity |
African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey |
Storage |
Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details. |
Background |
The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC. For purposes of this document, we refer to all forms of stable Terminal Complement Complex interchangeably as TCC and SC5b-9, recognizing that other complement regulatory proteins, like Clusterin, also form these stable complexes and are detectable in the SC5b-9 Plus assay. The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the concentration of TCC thereby giving an indication of the status of the terminal complement pathway in the specimen. It uses a monoclonal antibody to the C9 ring of TCC to capture the complex. The trapped TCC is subsequently detected with HRP-conjugated antibodies that bind to antigens of the SC5b-9 complex. This test, which provides a rapid, highly specific and quantitative procedure for measuring TCC levels, is designed for investigations studying the role or status of terminal complement pathway activation in numerous research settings, and for monitoring the generation of SC5b-9 complexes in vivo or in vitro. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2014 | ELISA |
Human |
Plasma |
Neuromyelitis optica |
|
2016 | ELISA |
Human |
ARPE-19 Cells |
||
2017 | ELISA |
Human |
Serum |
Diabetes |
|
2017 | ELISA |
Human |
Plasma |
Hereditary Angioedema |
|
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. |
2018 | ELISA |
Human |
Serum |
Microvesicles with heme |
2019 | ELISA |
Human |
Plasma |
Chronic Lymphocytic Leukemia |
|
2019 | ELISA |
Human |
Serum |
Chronic Lymphocytic Leukemia |
|
Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy |
2019 | ELISA |
Human |
Urine |
Diabetic nephropathy |
2019 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
2019 | ELISA |
Human |
Plasma |
aHUS |
|
Complement factor H contributes to mortality in humans and mice with bacterial meningitis. |
2019 | ELISA |
Human |
CSF |
Bacterial meningitis |
Complement fragments are biomarkers of antibody-mediated endothelial injury. |
2019 | ELISA |
Human |
Plasma |
Antibody-mediated endothelial injury |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Plasma |
FSGS |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Serum |
FSGS |
2020 | ELISA |
Human |
Serum |
SiNP coated proteins |
|
2020 | ELISA |
Human |
Plasma |
COVID-19 |
|
Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. |
2019 | ELISA |
Human |
Urine |
FSGS, MN, IgAN, LN, AAV, or MPGN |
Complement activation and endothelial perturbation parallel COVID-19 severity and activity. |
2020 | ELISA |
Human |
Plasma |
COVID-19 |
2020 | ELISA |
Human |
Serum |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2020 | ELISA |
Human |
Urine |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2020 | ELISA |
Human |
Plasma |
P-MAPA |
|
2020 | ELISA |
Human |
Plasma |
Thrombotic Microangiopathy - TA |
|
2021 | ELISA |
Human |
Serum |
COVID-19 |
|
2021 | ELISA |
Human |
Glomular Endothelial Cells |
Supernatent |
|
2021 | ELISA |
Human |
Plasma |
MPGN |
|
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Plasma |
C3G |
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Urine |
C3G |
2021 | ELISA |
Human |
Plasma |
Thrombotic Microangiopathy - TA |
|
2021 | ELISA |
Human |
Plasma |
||
Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports. |
2021 | ELISA |
Human |
Plasma |
Glomerulonephritis |
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. |
2021 | ELISA |
Human |
Plasma |
Lupus Nephritis |
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
Cancer, COVID-19 |
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
COVID-19 |
Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. |
2021 | ELISA |
Human |
Serum |
aHUS |
Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. |
2021 | ELISA |
Human |
Urine |
aHUS |
Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. |
2021 | ELISA |
Human |
Plasma |
COVID-19 |
2022 | ELISA |
Human |
Plasma |
aHUS |
|
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2021 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Serum |
COVID-19 |
|
2022 | ELISA |
Human |
Plasma |
Antiphospholipid syndrome |
|
Mechanism of Borrelia immune evasion by FhbA-related proteins |
2022 | ELISA |
Human |
Plasma |
Borrelia hermsii |
2022 | ELISA |
Human |
Plasma |
Heat-related illnesses |
|
2022 | ELISA |
Human |
Serum |
Myeloperoxidase-ANCA-associated glomerulonephritis |
|
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis. |
2022 | ELISA |
Human |
Urine |
AAV, FSGS, IgAN, MN, and LN |
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Whole Blood |
B. jararaca venom |
|
2022 | ELISA |
Human |
Plasma |
Thrombotic Microangiopathy - DI |
|
2022 | ELISA |
Human |
Plasma |
Thrombotic Microangiopathy - DI |
|
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Plasma |
Hemodialysis |
|
Complement activation during cardiopulmonary bypass and association with clinical outcomes. |
2022 | ELISA |
Human |
Plasma |
Cardiopulmonary bypass |
Indices of complement activation and coagulation changes in trauma patients |
2022 | ELISA |
Human |
Plasma |
Trauma |
C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome. |
2022 | ELISA |
Human |
Plasma |
COVID-19 |
2023 | ELISA |
Human |
Plasma, Serum |
Glomerulonephritis |
|
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury |
2009 | ELISA |
Human |
ARPE-19 Cells |
|
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease |
2011 | ELISA |
Human |
Serum |
|
2011 | ELISA |
Human |
Plasma |
Lymphatic filariasis |
|
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function |
2012 | ELISA |
Human |
Serum |
GEnCs and HUVEC exposed |
2012 | ELISA |
Human |
Plasma |
||
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Ear Fluid (MEE) |
|
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Serum |
|
2013 | ELISA |
Human |
CSF |
||
Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent. |
2013 | ELISA |
Human |
Serum |
|
In Vitro Hematological and In Vivo Vasoactivity Assessment of Dextran Functionalized Graphene |
2013 | ELISA |
Human |
Plasma |
|
2014 | ELISA |
Human |
Serum |
||
2014 | ELISA |
Human |
Plasma |
Lupus Nephritis |
|
Defining the complement biomarker profile of C3 glomerulopathy |
2014 | ELISA |
Human |
Plasma |
C3G |
2014 | ELISA |
Human |
Serum |
SPIO nanoworms |
|
2015 | ELISA |
Human |
Plasma |
Stx-HUS |
|
2015 | ELISA |
Human |
Serum |
Premolis semirufa caterpillar bristle extract |
|
Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis |
2014 | ELISA |
Human |
CSF |
Listeria meningitis |
2015 | ELISA |
Human |
Plasma |
||
2015 | ELISA |
Human |
Serum |
||
2016 | ELISA |
Human |
Serum |
Nanoparticles incubated |
|
2016 | ELISA |
Human |
Serum |
||
Inflammatory Response in Preterm and Very Preterm Newborns with Sepsis |
2016 | ELISA |
Human |
Serum |
|
2016 | ELISA |
Human |
Serum |
||
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation |
2016 | ELISA |
Human |
Plasma |
Imprime yeast treated |
2017 | ELISA |
Human |
Peritoneal dialysis fluid |
||
2017 | ELISA |
Human |
Serum |
Trauma, newborn brain |
|
Effect of Immobilized Antithrombin III on the Thromboresistance of Polycarbonate Urethane |
2017 | ELISA |
Human |
Serum |
|
Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo |
2017 | ELISA |
Human |
Serum |
|
2017 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs |
2018 | ELISA |
Human |
Serum |
Fc activation |
2018 | ELISA |
Human |
Serum |
B. lanceolatus venom |
|
2020 | ELISA |
Human |
Plasma |
Immune‐mediated thrombotic thrombocytopenic purpura |
|
1996 | ELISA |
Human |
Plasma |
Systemic Lupus Erythematosus |
|
2023 | ELISA |
Human |
Plasma |
Diabetes |
|
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. |
2023 | ELISA |
Human |
Serum |
COVID-19 |
2024 | ELISA |
Human |
Plasma |
Diabetes, Type 1 |
|
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid |
2024 | ELISA |
Human |
Serum |
COVID-19 |
2024 | ELISA |
Human |
Plasma |
C3G |
|
2024 | ELISA |
Human |
Urine |
FSGS, MCD |
|
2017 | ELISA |
Mouse |
Serum |